Of note, a previous study also reported that a low peripheral blood CD4+:CD8+ T cell ratio was associated with longer progression-free survival and overall survival in a cohort of patients receiving palliative chemotherapy for initially unresectable recurrent/metastatic HNSCC [49]. Here, CD4 is linked to head and neck squamous cell carcinoma.